Carbon nanotubes may cause cancer, study reveals

A new study conducted by a team of UK and US scientists has revealed the carcinogenic potential of certain carbon nanotubes. In a paper published in Nature Nanotechnology on 20 May, the researchers describe asbestos-like features in long, multi-walled carbon nanotubes (MWCNTs), when they are inhaled in sufficient quantities.

In order to analyse their risk potential, long and short nanotubes, long and short asbestos fibres as well as carbon black were injected into the abdominal cavity of mice. 'The results were clear,' says Professor Kenneth Donaldson, who is a co-author of the study and led the research at the University of Edinburgh, UK. 'Long, thin carbon nanotubes showed the same effects as long, thin asbestos fibers,' the effect being that they have the potential to cause mesothelioma.

Mesothelioma is a cancer of the lung lining that can take 30 to 40 years to appear after a person has been exposed to a harmful substance. In the 1940s, asbestos was revealed to cause mesothelioma, and even now, after its usage has been drastically reduced, asbestos-related cancers are likely to continue for several more decades.

Now, this study has raised the same concerns about MWCNTs. However, some questions have not been answered yet, Professor Donaldson says: "We still don't know whether carbon nanotubes will become airborne and be inhaled, or whether, if they do reach the lungs, they can work their way into the sensitive outer lining. But if they do get there in sufficient quantity, there is a chance that some people will develop cancer - perhaps decades after breathing the stuff."

Dr Andrew Maynard, another co-author of the paper and chief scientific advisor to the Project on Emerging Nanotechnologies, believes that the industry as well as policy-makers will have to react quickly to the threat. Workplaces and products need to be made safe, while from a policy perspective "we've got to make sure that everything is in place to enable us to really take advantage of what is quite an incredible technology as safely as possible," Dr Maynard states.

"We need policies that ensure the right research is done, so that we understand not only what makes some nanotubes harmful, but also how to make them safely. And one of the things that recent research does show is that it is possible to make nanotubes safe, certainly with regard to causing mesothelioma."

"This is a wakeup call for nanotechnology in general and carbon nanotubes in particular," Dr Maynard adds. "As a society, we cannot afford not to exploit this incredible material, but neither can we afford to get it wrong - as we did with asbestos."

MWCNTs are made up of multiple concentric layers of graphite or a single layer of graphite rolled around itself multiple times. They produce extremely light, though strong composite materials and are currently used by the automotive industry, in silicon chip manufacturing, electronics and in sporting goods.

Future fields of application are extensive and include catalysts, solar cells, batteries, fuel cells and sensors as well as innovative medical surfaces and new drugs. According to the Project on Emerging Nanotechnologies, the total global market value of carbon nanotubes is expected to exceed USD 1.9 billion (€1.2 billion) by the year 2010.

For further information, please visit:
http://www.nanotechproject.org/
http://www.nano.org.uk/
http://www.safenano.org/

Copyright ©European Communities, 2008
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...